OECD Health Working Papers
This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language - English or French - with a summary in the other.
- ISSN: 18152015 (online)
- https://doi.org/10.1787/18152015
Pharmaceutical Pricing and Reimbursement Policies in Germany
This paper describes pharmaceutical pricing and reimbursement policies in Germany, considering
them in the broader environment in which they operate, and assesses their impact on the achievement of a
number of policy goals. Pharmaceutical coverage is comprehensive, with a high level of public funding,
and ensures access to treatments. However, recent increases in out-of-pocket payments may impair
affordability for the poorest part of the population. Germany does not regulate ex-manufacturer prices of
pharmaceuticals at market entry (though distribution margins are regulated for reimbursed drugs). On the
other hand, maximum reimbursement amounts (known as reference prices) are set for products which can
be clustered in groups of equivalent (generic) or comparable products (...)
JEL:
I11: Health, Education, and Welfare / Health / Analysis of Health Care Markets;
I18: Health, Education, and Welfare / Health / Health: Government Policy; Regulation; Public Health
- Click to access:
-
Click to download PDF - 1.26MBPDF
-
Click to Read online and shareREAD